Parkin as a tumor suppressor gene for hepatocellular carcinoma (original) (raw)

• Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H et al. (2003). Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25–q27. Proc Natl Acad Sci USA 100: 5956–5961.
  Article CAS PubMed PubMed Central Google Scholar
• Chen YG, Lui HM, Lin SL, Lee JM, Ying SY . (2002). Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med (Maywood) 227: 75–87.
  Article CAS Google Scholar
• Dawson TM, Dawson VL . (2003). Molecular pathways of neurodegeneration in Parkinson′s disease. Science 302: 819–822.
  Article CAS PubMed Google Scholar
• De Groot E, Veltmaat J, Caricasole A, Defize L, van den Eijnden-van Raaij A . (2000). Cloning and analysis of the mouse follistatin promoter. Mol Biol Rep 27: 129–139.
  Article CAS PubMed Google Scholar
• Denison SR, Wang F, Becker NA, Schule B, Kock N, Phillips LA et al. (2003). Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene 22: 8370–8378.
  Article CAS PubMed Google Scholar
• Endo Y, Marusawa H, Kinoshita K, Morisawa T, Sakurai T, Okazaki IM et al. (2007). Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappa B signaling. Oncogene 26: 5587–5595.
  Article CAS PubMed Google Scholar
• Farazi PA, DePinho RA . (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674–687.
  Article CAS PubMed Google Scholar
• Farrer MJ . (2006). Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 7: 306–318.
  Article CAS PubMed Google Scholar
• Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, Lian Z . (2002). Genetic mechanisms of hepatocarcinogenesis. Oncogene 21: 2593–2604.
  Article CAS PubMed Google Scholar
• Germann A, Dihlmann S, Hergenhahn M, Doeberitz MK, Koesters R . (2003). Expression profiling of CC531 colon carcinoma cells reveals similar regulation of beta-catenin target genes by both butyrate and aspirin. Int J Cancer 106: 187–197.
  Article CAS PubMed Google Scholar
• Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A et al. (2003). Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278: 43628–43635.
  Article CAS PubMed Google Scholar
• Grusch M, Drucker C, Peter-Vorosmarty B, Erlach N, Lackner A, Losert A et al. (2006). Deregulation of the activin/follistatin system in hepatocarcinogenesis. J Hepatol 45: 673–680.
  Article CAS PubMed Google Scholar
• Hahn WC, Weinberg RA . (2002). Rules for making human tumor cells. N Engl J Med 347: 1593–1603.
  Article CAS PubMed Google Scholar
• Harrison CA, Gray PC, Vale WW, Robertson DM . (2005). Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol Metab 16: 73–78.
  Article CAS PubMed Google Scholar
• Hully JR, Chang L, Schwall RH, Widmer HR, Terrell TG, Gillett NA . (1994). Induction of apoptosis in the murine liver with recombinant human activin A. Hepatology 20: 854–862.
  Article CAS PubMed Google Scholar
• Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA et al. (2003). Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 12: 2277–2291.
  Article CAS PubMed Google Scholar
• Jackson PK, Eldridge AG, Freed E, Furstenthal L, Hsu JY, Kaiser BK et al. (2000). The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol 10: 429–439.
  Article CAS PubMed Google Scholar
• Jiang H, Jiang Q, Liu W, Feng J . (2006). Parkin suppresses the expression of monoamine oxidases. J Biol Chem 281: 8591–8599.
  Article CAS PubMed Google Scholar
• Kahle PJ, Haass C . (2004). How does parkin ligate ubiquitin to Parkinson's disease? EMBO Rep 5: 681–685.
  Article CAS PubMed PubMed Central Google Scholar
• Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S et al. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605–608.
  Article CAS PubMed Google Scholar
• Kitao Y, Imai Y, Ozawa K, Kataoka A, Ikeda T, Soda M et al. (2007). Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation. Hum Mol Genet 16: 50–60.
  Article CAS PubMed Google Scholar
• Kogure K, Zhang YQ, Maeshima A, Suzuki K, Kuwano H, Kojima I . (2000). The role of activin and transforming growth factor-beta in the regulation of organ mass in the rat liver. Hepatology 31: 916–921.
  Article CAS PubMed Google Scholar
• Kong FM, Anscher MS, Washington MK, Killian JK, Jirtle RL . (2000). M6P/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene 19: 1572–1578.
  Article CAS PubMed Google Scholar
• Kou T, Marusawa H, Kinoshita K, Endo Y, Okazaki IM, Ueda Y et al. (2006). Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. Int J Cancer 120: 469–476.
  Article Google Scholar
• Laurent-Puig P, Zucman-Rossi J . (2006). Genetics of hepatocellular tumors. Oncogene 25: 3778–3786.
  Article CAS PubMed Google Scholar
• Lengauer C, Kinzler KW, Vogelstein B . (1998). Genetic instabilities in human cancers. Nature 396: 643–649.
  Article CAS PubMed Google Scholar
• Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I et al. (2003). HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 22: 2729–2740.
  Article CAS PubMed PubMed Central Google Scholar
• Matsumoto T, Marusawa H, Endo Y, Ueda Y, Matsumoto Y, Chiba T . (2006). Expression of APOBEC2 is transcriptionally regulated by NF-kappaB in human hepatocytes. FEBS Lett 580: 731–735.
  Article CAS PubMed Google Scholar
• Millikin D, Meese E, Vogelstein B, Witkowski C, Trent J . (1991). Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma. Cancer Res 51: 5449–5453.
  CAS PubMed Google Scholar
• Morett E, Bork P . (1999). A novel transactivation domain in parkin. Trends Biochem Sci 24: 229–231.
  Article CAS PubMed Google Scholar
• Morita R, Saito S, Ishikawa J, Ogawa O, Yoshida O, Yamakawa K et al. (1991). Common regions of deletion on chromosomes 5q, 6q, and 10q in renal cell carcinoma. Cancer Res 51: 5817–5820.
  CAS PubMed Google Scholar
• Negrini M, Sabbioni S, Possati L, Rattan S, Corallini A, Barbanti-Brodano G et al. (1994). Suppression of tumorigenicity of breast cancer cells by microcell-mediated chromosome transfer: studies on chromosomes 6 and 11. Cancer Res 54: 1331–1336.
  CAS PubMed Google Scholar
• Nikolaev AY, Li M, Puskas N, Qin J, Gu W . (2003). Parc: a cytoplasmic anchor for p53. Cell 112: 29–40.
  Article CAS PubMed Google Scholar
• Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M et al. (2004). Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279: 18614–18622.
  Article CAS PubMed Google Scholar
• Patella S, Phillips DJ, Tchongue J, De Kretser DM, Sievert W . (2006). Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis. Am J Physiol Gastrointest Liver Physiol 290: G137–G144.
  Article CAS PubMed Google Scholar
• Perez FA, Palmiter RD . (2005). Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci USA 102: 2174–2179.
  Article CAS PubMed PubMed Central Google Scholar
• Picchio MC, Martin ES, Cesari R, Calin GA, Yendamuri S, Kuroki T et al. (2004). Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin Cancer Res 10: 2720–2724.
  Article CAS PubMed Google Scholar
• Rodgarkia-Dara C, Vejda S, Erlach N, Losert A, Bursch W, Berger W et al. (2006). The activin axis in liver biology and disease. Mutat Res 613: 123–137.
  Article CAS PubMed Google Scholar
• Rodriguez C, Causse A, Ursule E, Theillet C . (2000). At least five regions of imbalance on 6q in breast tumors, combining losses and gains. Genes Chromosomes Cancer 27: 76–84.
  Article CAS PubMed Google Scholar
• Rossmanith W, Chabicovsky M, Grasl-Kraupp B, Peter B, Schausberger E, Schulte-Hermann R . (2002). Follistatin overexpression in rodent liver tumors: a possible mechanism to overcome activin growth control. Mol Carcinog 35: 1–5.
  Article CAS PubMed Google Scholar
• Saito S, Sirahama S, Matsushima M, Suzuki M, Sagae S, Kudo R et al. (1996). Definition of a commonly deleted region in ovarian cancers to a 300-kb segment of chromosome 6q27. Cancer Res 56: 5586–5589.
  CAS PubMed Google Scholar
• Schwall RH, Robbins K, Jardieu P, Chang L, Lai C, Terrell TG . (1993). Activin induces cell death in hepatocytes in vivo and in vitro. Hepatology 18: 347–356.
  CAS PubMed Google Scholar
• Seglen PO . (1976). Preparation of isolated rat liver cells. Methods Cell Biol 13: 29–83.
  Article CAS PubMed Google Scholar
• Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S et al. (2000). Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25: 302–305.
  Article CAS PubMed Google Scholar
• Takabe K, Wang L, Leal AM, Macconell LA, Wiater E, Tomiya T et al. (2003). Adenovirus-mediated overexpression of follistatin enlarges intact liver of adult rats. Hepatology 38: 1107–1115.
  Article CAS PubMed Google Scholar
• Takahashi R, Imai Y, Hattori N, Mizuno Y . (2003). Parkin and endoplasmic reticulum stress. Ann NY Acad Sci 991: 101–106.
  Article CAS PubMed Google Scholar
• Tanaka Y, Marusawa H, Seno H, Matsumoto Y, Ueda Y, Kodama Y et al. (2006). Anti-viral protein APOBEC3G is induced by interferon-a stimulation in human hepatocytes. Biochem Biophys Res Commun 341: 314–319.
  Article CAS PubMed Google Scholar
• Tibiletti MG, Bernasconi B, Furlan D, Riva C, Trubia M, Buraggi G et al. (1996). Early involvement of 6q in surface epithelial ovarian tumors. Cancer Res 56: 4493–4498.
  CAS PubMed Google Scholar
• Toda Y, Kono K, Abiru H, Kokuryo K, Endo M, Yaegashi H et al. (1999). Application of tyramide signal amplification system to immunohistochemistry: a potent method to localize antigens that are not detectable by ordinary method. Pathol Int 49: 479–483.
  Article CAS PubMed Google Scholar
• Trent JM, Stanbridge EJ, McBride HL, Meese EU, Casey G, Araujo DE et al. (1990). Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science 247: 568–571.
  Article CAS PubMed Google Scholar
• Von Coelln R, Thomas B, Savitt JM, Lim KL, Sasaki M, Hess EJ et al. (2004). Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci USA 101: 10744–10749.
  Article CAS PubMed PubMed Central Google Scholar
• Wang F, Denison S, Lai JP, Philips LA, Montoya D, Kock N et al. (2004). Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer 40: 85–96.
  Article CAS PubMed Google Scholar
• West AB, Dawson VL, Dawson TM . (2005). To die or grow: Parkinson's disease and cancer. Trends Neurosci 28: 348–352.
  Article CAS PubMed Google Scholar
• Willert J, Epping M, Pollack JR, Brown PO, Nusse R . (2002). A transcriptional response to Wnt protein in human embryonic carcinoma cells. Bio Med Central Dev Biol 2: 8.
  Google Scholar